Valedictory lecture

A new app provides dynamic predictions of survival for patients suffering from soft tissue sarcoma. It was developed by the mathematical Institute research group DASPO, Data Analysis and Survival for Personalised Oncology.

Promotores: Prof.dr. P.C.W. Hogendoorn & Prof.dr. H.P. Spaink, Co-promotor: Dr. B.E. Snaar-Jagalska

PhD student Janine Westendorp and her colleagues conducted literature research on what patients with cancer and their loved ones perceive as harmful communication from healthcare providers. The results were published in the journal Psycho-Oncology and are released as a poster to distribute to healthcare…

Theoretical physicist Luca Giomi receives a 2 million euro ERC Consolidator Grant for research into flowing cells in a strange hexatic phase, which is half fluid, half solid.

Chemotherapy, but without hair loss or extreme fatigue. It may be possible if the toxic drug only becomes active where it is ‘switched on’ by light. Matthijs Hakkennes has helped bring that idea closer to reality and obtained his PhD cum laude. ‘I received many thank-you emails from China and Bangla…

The Leiden Institute of Physics has been awarded three out of twelve available grants from the FOM Projectruimte. Principal Investigators Milan Allan, Stefan Semrau and Carlo Beenakker all receive around 400,000 euro for their research.

Nausea, neurologic pain and hair loss: some of the severe side effects of chemotherapy. Not necessary, biochemist Liyan Zhang showed. Together with Leiden biologists and others, she achieved great results with a drug that is only active in combination with light. Zhang will defend her PhD on 4 July.

The DASPO-group for data analysis and survival in personalized sarcoma at the Mathematical Institute has developed an app that provides personalised predictions for patients suffering from soft tissue sarcomas. Due to the aggressive nature of such tumors, the prognosis for such patients is poor, even…

A month ago it was Marc Baggelaar, and now Hans Kistemaker too has obtained his PhD cum laude at the Leiden Institute for Chemistry (LIC). ‘He has made ground-breaking contributions to the world of protein modification,’ says PhD supervisor Gijs van der Marel. Kistemaker obtained his PhD on 11 May…

Chemotherapy that does nothing until you irradiate it with light. Sylvestre Bonnet receives a Vici grant of 1.5 million euros for the development of this treatment. The Leiden chemist wants to build a new molecule to fight tumours that are at the time still difficult to treat.

Leiden has a long history in the treatment of blood cell cancer. Research to find better therapies never stands still. One of the potential treatments currently being worked on is a ‘living medicine’.

Doctors should work with patients with bone and soft-tissue tumours to find the best personal treatment strategy says Prof. Michiel den de Sande. He has developed an app that helps choose the right treatment. Van de Sande was appointed Professor of Orthopaedics with a particular focus on paediatric…

Lecture

Treatment and care for cancer patients is becoming increasingly advanced. For example, surgeons can now perform operations with much greater precision, and therapeutic vaccines are being developed to prompt the patient’s immune system to fight cancer. Work is also being done on better early diagnostics,…

Key publications of the Cancer Drug Target Discovery group

New or improved treatments for chronic and acute illness.

Improving health, enhancing well-being and reducing health disparities across society.

More and more medicines are becoming available that target a tumour’s specific traits. The use of chemotherapy is continually undergoing improvement.

Pathways of toxicity

What is the most effective way to eliminate tumour cells? The DNA repair mechanism could play an important role in increasing the effectiveness of chemotherapy in the fight against cancerous cells. If we are to influence this mechanism, we need fundamental knowledge about how the mechanism works.

PhD defence

The research conducted at the Leiden Academic Centre for Drug Research is clustered within the divisions of BioTherapeutics, Cell Systems and Drug Safety, Medicinal Chemistry and Systems Pharmacology and Pharmacy, and the Metabolomics and Analytics Centre.

Providing each cancer patient with the right treatment remains a challenge. Oncode Accelerator aims to change this by innovating the way we develop cancer treatments, thus ensuring the patient is at the heart of the process. Leiden University, the LUMC and other partners will implement this new way…

Coordination chemistry is the chemistry of metal atoms

Pancreatic ductal adenocarcinoma (PDAC) is the deadliest common cancer, with only 8% of patients surviving for five years. One reason for this poor outcome is that current chemotherapy treatments are highly toxic, often leaving patients too sick to receive treatment or forcing doctors to lower the dose…

Helping cancer patients with treatment choices.

Joost Beltman (LACDR, Leiden University) has provided novel insights in the way T cells migrate towards virus-infected cells. This was accomplished by a combination of experimental research in the group of Ton Schumacher (Dutch Cancer Institute, NKI) and computer simulations in collaboration with Rob…

We study how communication can heal and harm when patients are confronted with an illness. Most of our studies focus on serious illnesses such as advanced cancer. Communication lies at the heart of medicine, yet we do not always know which specific communication helps patients. Moreover, many complaints…

PhD defence

To get a feeling of how we operate at LED3 when it comes to Early Drug Discovery, please browse through our case studies. When you select a case study you’ll find relevant contacts.

Molecular Physiology is a research group at the Leiden Institute of Chemistry dedicated to the design, synthesis and application of chemical tools to study important biological and biomedical questions. The group is headed by Prof. Dr. Mario van der Stelt and includes the research lines of Assistant…

Our research in the area of safety sciences aims to increase the mechanistic understanding of cellular toxicity of drugs and, in a broader sense, chemicals.

PhD defence

Inactivating mutations in BRCA1 or BRCA2 genes predispose to several types of cancer.

Glycosidases (GHs) are enzymes responsible for the degradation of carbohydrates and play many roles in human health and pathophysiology. Often, abnormal levels of glycosidase activity are markedly linked to human pathologies.

Source: Nature Biotechnology, Volume 2014, Issue June (2014)

Overkleeft

These awards honour researchers who turn scientific insight into real-world impact. From master’s students to postdocs, they highlight exceptional work in life sciences, health sciences, biotech, or environmental health sciences with data science at the core. Meet the 2025 winners.

Metal-containing molecules combine geometrical features and a reactivity that are inherently different from that of organic molecules. My research focuses on light-activatable metal-based anticancer drugs and metal-functionalized liposomes. Light is a very selective way to activate photosensitive drugs…

As part of a wish fulfilment from Make-A-Wish, Leiden University recently welcomed a very special guest. Together with her best friend, Yuliia participated in a practical session on February 24th, where they studied the brain of a calf.

Promotor: E. Bouwman, Co-promotor: S. Bonnet

The majority (80%) of e-waste generated globally are recycled informally in developing countries.

Promotor: H.S. Overkleeft, J. Neefjes, Co-promotor: M. van der Stelt

PhD defence

PhD defence

An overview of the research at the Biologics Formulation group